C406 CAR T / Shanghai Puheng Biotechnology, Jinan Central Hospital - LARVOL DELTA

Phase I summary of the C406 (CART) efficacy and safety for an HER-2–positive breast cancer population. (ASCO 2025) - P=N/A | "Cyclophosphamide combined with fludarabine was the regimen for lymphocyte clearance in all patients...Bridging treatment options for other patients were as follows, attillizumab bridging therapy (n = 1), albumin-bound paclitaxel combined with carboplatin and attillizumab (n = 1), albumin-bound paclitaxel combined with Attillizumab (n = 2), gemcitabine combined with attillizumab (n = 1), Albumin-bound paclitaxel + epirubicin + cyclophosphamide + Attilizumab + local radiotherapy (n = 1), docetaxel + Attilizumab + local radiotherapy (n = 1)... C406 therapy showed an acceptable safety profile anti-tumor activity for advanced HER-2 positive breast cancer, but the antitumor activity needs to be further explored."

Clinical • P1 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2